Posted by Michael Wonder on 11 Jun 2026
Italfarmaco announces Health Canada acceptance and priority review of new drug submission for givinostat as a Duchenne muscular dystrophy treatment
10 June 2026 - New drug submission is based on Italfarmaco’s Phase 3 EPIDYS trial data demonstrating meaningful treatment benefits in Duchenne muscular dystrophy patients.
Italfarmaco today announced that Health Canada has accepted for review the new drug submission for givinostat (Duvyzat) for the treatment of Duchenne muscular dystrophy.
